Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Thomas

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Hematological Oncology|April 22, 2025
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort StudyPallawi Torka, Natalie S Grover, Timothy J Voorhees, et al.
Blood Cancer Journal|October 18, 2024
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort studyNatalie S Grover, Kaitlin Annunzio, Marcus Watkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2025
The magnitude of legal wildlife trade and implications for species survivalBenjamin Michael Marshall, Aubrey L Alamshah, Pedro Cardoso, et al.
Nature Cell Biology|July 3, 2026
Author Correction: Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistancePatrizia Romani, Nunzia Nirchio, Mattia Arboit, et al.
Nature Cell Biology|February 15, 2022
Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistancePatrizia Romani, Nunzia Nirchio, Mattia Arboit, et al.
Blood Advances|June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Blood Advances|October 21, 2022
Postibrutinib relapse outcomes for patients with marginal zone lymphomaNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Hematological Oncology|April 22, 2025
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort StudyPallawi Torka, Natalie S Grover, Timothy J Voorhees, et al.
Blood Cancer Journal|October 18, 2024
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort studyNatalie S Grover, Kaitlin Annunzio, Marcus Watkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2025
The magnitude of legal wildlife trade and implications for species survivalBenjamin Michael Marshall, Aubrey L Alamshah, Pedro Cardoso, et al.
Nature Cell Biology|July 3, 2026
Author Correction: Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistancePatrizia Romani, Nunzia Nirchio, Mattia Arboit, et al.
Nature Cell Biology|February 15, 2022
Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistancePatrizia Romani, Nunzia Nirchio, Mattia Arboit, et al.
Blood Advances|June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.
Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Blood Advances|October 21, 2022
Postibrutinib relapse outcomes for patients with marginal zone lymphomaNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 6